TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT07137910: An Open-Label, Multicenter, Phase 2 Study to Evaluate the Efficacy and Safety of AHB-137 Injection in Participants With Low-HBsAg Chronic Hepatitis B

Sponsor: Ausper Biopharma Co., Ltd. · Phase: PHASE2 · Area: INFECTIOUS_VACCINE · Target Enrollment: 200 pts

Competing Trials Overlap

2 Active Trials

Excess Burn Exposure

$4,968,600

Rescue Site Savings

+$3,292,800

Unlock Full NCT07137910 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07137910 Rescue Dossier →